MARKET

SGEN

SGEN

Seattle Genetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

117.00
-1.33
-1.12%
After Hours: 117.12 +0.12 +0.10% 17:23 02/21 EST
OPEN
118.34
PREV CLOSE
118.33
HIGH
119.82
LOW
116.55
VOLUME
898.62K
TURNOVER
--
52 WEEK HIGH
124.32
52 WEEK LOW
62.90
MARKET CAP
20.15B
P/E (TTM)
-120.6061
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SGEN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SGEN stock price target is 125.75 with a high estimate of 165.00 and a low estimate of 95.00.

EPS

SGEN News

More
  • Seattle Genetics bladder drug gets breakthrough therapy designation
  • American City Business Journals · 3d ago
  • Five Prime up 5% on Seattle Genetics license deal
  • Seeking Alpha - Article · 3d ago
  • Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates
  • Zacks · 3d ago
  • Seattle Genetics' PADCEV nabs accelerated review for first-line bladder cancer
  • Seeking Alpha - Article · 3d ago

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About SGEN

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.
More

Webull offers kinds of Seattle Genetics, Inc. stock information, including NASDAQ:SGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGEN stock news, and many more online research tools to help you make informed decisions.